Figure 5.
RPL32 Silencing Inhibits the Growth of Lung Cancer In Vivo
(A) Sequence of the CpG-linked human RPL32 siRNA conjugate (CpG-RPL32 siRNA). CpG sequence (deoxyribonucleotides shown in black) were phosphorothioated and connected through a carbon linker (6 of C3 units) to the antisense strand of RPL32 siRNA (ribonucleotides shown in red). (B) Body weight of NSG mice inoculated with 5 × 106 A549 cells and randomly assigned to be injected peritumorally with PBS, CpG-scrambled RNA, or CpG-RPL32 siRNA. (C and D) Tumor volume (C) and weight (D) in each group. **p < 0.01. (E) Xenograft tumors in each group. (F) Tumor lysates from each group (n = 3) were subjected to immunoblot analysis to validate the RPL32 knockdown efficiency and p53 accumulation.